Invesco Ltd. Tcr2 Therapeutics Inc. Transaction History

Invesco Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $61,459 - $111,914	-13,419 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $10,119 - $22,001	1,199 Added 9.81%	13,419 $114,000
Q2 2021 Aug 17, 2021	BUY	$16.41 - $24.71 $200,530 - $301,956	12,220 New	12,220 $201,000
Q1 2021 May 17, 2021	SELL	$20.38 - $34.07 $4.17 Million - $6.97 Million	-204,486 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $3.04 Million - $5.22 Million	159,877 Added 358.4%	204,486 $6.32 Million

Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $42,522 - $67,159	3,246 Added 7.85%	44,609 $907,000
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $269,273 - $696,966	41,363 New	41,363 $636,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.